Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam

AIDS Research and Human Retroviruses

Volumn 25, Issue 2, 2009, Pages 175-182

  Ishizaki, Azumi ^a   Cuong, Nguyen Hung ^b   Thuc, Pham Van ^b   Trung, Nguyen Vu ^c   Saijoh, Kiyofumi ^a   Kageyama, Seiji ^a   Ishigaki, Kyoko ^d   Tanuma, Junko ^d   Oka, Shinichi ^d   Ichimura, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Hai Phong Medical University   (Viet Nam)

^c HANOI MEDICAL UNIVERSITY   (Viet Nam)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD DONOR; CHINA; CODON; DATA BASE; DRUG USE; FEMALE; FEMALE SEX WORKER; GENE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PLASMA; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAILOR; VIET NAM; VIRUS RESISTANCE; WORKER;

ADOLESCENT; ADULT; AGED; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIETNAM; VIRAL PROTEINS; YOUNG ADULT;

EID: 60849084495     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0193     Document Type: Article

References (47)

1. UNAIDS/WHO: ASIA AIDS epidemic update Regional Summary. UNAIDS 2008.
2. UNAIDS/WHO: Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections. UNAIDS 2006.
3. Nguyen TA, Hoanh LT, Pham VQ, and Detels R: Risk factors for HIV-1 seropositivity in drug users under 30 years old in Haiphong, Vietnam. Addiction 2001;96(3):405-413.
4. Nguyen AT, Fylkesnes K, Thang BD, et al.: Human immunodeficiency virus (HIV) infection patterns and risk behaviors in different population groups and provinces in Viet Nam. Bull WHO 2007;85(1):35-41.
5. UNAIDS: The United Nations General Assembly Special Session on HIV/AIDS Country progress report; Viet Nam. UNAIDS 2008.
6. Nguyen THL, Recordon-Pinson P, Pham VH, et al.: HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 study. Large predominance of CRF01-AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses 2003;19(10):925-928.
7. Nguyen TH, Nguyen BD, Shrivastava R, et al.: HIV drug resistance threshold survey using specimens from voluntary counseling and testing sites in Hanoi, Vietnam. Antiviral Ther 2008;13(Suppl. 2):115-121.
8. Tran TTH, Maljkovic I, Swartling S, et al.: HIV-1 CRF01-AE in intravenous drug users in Hanoi, Vietnam. AIDS Res Hum Retroviruses 2004;20(3):341-345.
9. Caumont A, Nguyen THL, Nguyen TVU, et al.: Sequence analysis of env C2/V3, gag p17/p24, and pol protease regions of 25 HIV type 1 isolates from Ho Chi Minh City, Vietnam. AIDS Res Hum Retroviruses 2001;17(13):1285-1291.
10. Kato K, Shiino T, Kusagawa S, et al.: Genetic similarity of HIV type 1 subtype E in a recent outbreak among injecting drug users in northern Vietnam to strains in Guangxi Province of southern China. AIDS Res Hum Retroviruses 1999;15(13):1157-1168.
11. Kato K, Kusagawa S, Motomura K, et al.: Closely related HIV-1 CRF01-AE variant among injecting drug users in northern Vietnam: Evidence of HIV spread across the Vietnam-China border. AIDS Res Hum Retroviruses 2001;17(2):113-123.
12. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20(16):W13-23.
13. Lwembe R, Ochieng W, Panikulam A, et al: Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007;79(7):865-872.
14. Jonhson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16(1):62-68.
15. Luu TMC, Tran NN, Nai TH, et al.: HIV prevalence and risk behaviors among injecting drug users in Ho Chi Minh city, Hai Phong and Hanoi, Viet Nam. XVI International AIDS Conference. Toronto, Canada, 13-18 August 2006. Abstract CDC0320.
16. Tran TN, Detels R, Long HT, and Lan HP: Drug use among female sex workers in Hanoi, Vietnam. Addiction 2005;100(5):619-625.
17. Ministry of Health Viet Nam: Results from the HIV/STI integrated biological and behavioral surveillance (IBBS) in Viet Nam, 2005-2006. UNAIDS 2006.
18. Nerurkar VR, Nguyne HT, Dashwood WM, et al.: HIV type 1 subtype E in commercial sex workers and injection drug users in southern Vietnam. AIDS Res Hum Retroviruses 1996;12(9):841-843.
19. Nerurkar VR, Nguyen HT, Woodward CL, et al.: Sequence and phylogenetic analyses of HIV-1 infection in Vietnam: Subtype E in commercial sex workers (CSW) and infection drug users (IDU). Cell Mol Biol (Noisy-le-Grand) 1997;43(7):959-968.
20. Nguyen THL, Masquelier B, Pham VH, et al.: Further characterization of HIV-1 isolates from Ho Chi Minh City, Vietnam. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(1):93-95.
21. Menu E, Truong TX, Lafon ME, et al.: HIV type 1 Thai subtype E is predominant in South Vietnam. AIDS Res Hum Retroviruses 1996;12(7):629-633.
22. Beyrer C, Razak MH, Lisam K, et al.: Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS 2000;14(1):75-83.
23. Yu XF, Chen J, Shao Y, et al.: Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. J Acquir Immune Defic Syndr 1999;22(2):180-188.
24. Monitoring the AIDS Pandemic Network (MAP): Drug injection and HIV/AIDS in Asia. The MAP Reports 2005.
25. Jackson JB, Becker-Pergola G, Guay LA, et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14(11):F111-F115.
26. Liu J, Yue J, Wu S, and Yan Y: Polymorphisms and drug resistance analysis of HIV-1 CRF01-AE strains circulating in Fujian Province, China. Arch Virol 2007;152(10):1799-1805.
27. Ly N, Recordon-Pinson P, Viseth P, et al.: Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naïve to antiretroviral drugs. AIDS Res Hum Retroviruses 2005;21(11):971-976.
28. Han X, Zhang M, Dai D, et al.: Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: Baseline prevalence and subtype-specific difference. AIDS Res Hum Retroviruses 2007;23(3):357-364.
29. Sukasem C, Churdboonchart V, Sirisidthi K, et al.: Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: Implications for further epidemiologic surveillance. Jpn J Infect Dis 2007;60(5):284-289.
30. Yam WC, Chen JHK, Wong KH, et al.: Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01-AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol 2006;35(4):454-457.
31. Liu L, Lu HZ, Henry M, and Tamalet C: Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China. J Med Virol 2007;79(10):1593-1599.
32. Holguín A, Suñe C, Hamy F, et al.: Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 2006;36(4):264-271.
33. Ode H, Matsuyama S, Hata M, et al.: Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J Mol Biol 2007;370(3):598-607.
34. Sanches M, Krauchenco S, Martins NH, et al.: Structural characterization of B and non-B subtypes of HIV-protease: Insighs into the natural susceptibility to drug resistance development. J Mol Biol 2007;369(4):1029-1040.
35. Hsu LY, Subramaniam R, Bacheler L, and Paton NI: Characterization of mutations in CRF01-AE isolates from antiretroviral treatment-naive and experienced patients in Singapore. J Acquir Immune Defic Syndr 2005;38(1):5-13.
36. Ariyoshi K, Matsuda M, Miura H, et al.: Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01-AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003;33(3):336-342.
37. Kantor R, Katzenstein DA, Efron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reversed transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2(4):325-337.
38. Tee KK, Kamarulzaman A, and Ng KP: Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. Med Microbiol Immunol 2006;195(2):107-112.
39. Snoeck J, Kantor R, Shafer RW, et al.: Discordance between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006;50(2):694-701.
40. Baxter JD, Schapiro JM, Boucher CA, et al.: Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006;80(21):10794-10801.
41. De Meyer S, Vangeneugden T, Van Baelen B, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008;24(3):379-388.
42. Picchio G, Vingerhoets J, Staes M, et al.: Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008.
43. Kim EY, Winters MA, Kagan RM, and Merigan TC: Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. J Virol 2001;75(22):11227-11233.
44. Winters MA and Merigan TC: Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: Clinical impact and molecular mechanisms. Antimicrob Agents Chemother 2005;49(7):2575-2582.
45. Paolucci S, Baldanti F, Dossena L, and Gema G: Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility. Antiviral Res 2006;69(3):181-185.
46. Kozisek M, Saskova KG., Rezacova P, et al.: Ninety nine is not enough: Molecular characterization of inhibitor resistant HIV-1 protease mutants with insertions in the flap region. J Virol 2008;82(12):5869-5878.
47. Chen JHK, Wong KH, Chan KC, et al.: Molecular epidemiology and divergence of HIV type 1 protease codon 35 inserted strains among treatment-naive patient in Hong Kong. AIDS Res Hum Retroviruses 2008;24(4):537-542.